Anzeige
Meldung des Tages: Das „Next Butte?“-Setup in Montana — und es ist noch immer eine $15M-Story

AbbVie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
205,07 $
-1,16 $
-0,56%
177,57 € 20.03.26
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
5,85 EUR
Dividendenrendite
3,03%
Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter abwärts? Short handeln - Jetzt mit Hebel 12,14: VJ80U1
Werbung

AbbVie News

22.05.25 - PR Newswire
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire
16.05.25 - PR Newswire
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV PR Newswire
14.05.25 - PR Newswire
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-​tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression ...
14.05.25 - PR Newswire
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-​Generation siRNA Therapies Across Multiple Therapeutic Areas PR ...
13.05.25 - PR Newswire
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV PR Newswire
12.05.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders PR Newswire
09.05.25 - PR Newswire
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire
09.05.25 wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Heute im Fokus: Commerzbank, AbbVie, Colgate-Palmolive, Krones, Bechtle und PNE
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
08.05.25 - PR Newswire
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join - Contact The Gross Law Firm
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire
06.05.25 - PR Newswire
AbbVie to Present at the Bank of America Securities Healthcare Conference
AbbVie to Present at the Bank of America Securities Healthcare Conference PR Newswire
06.05.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV PR Newswire
05.05.25 - PR Newswire
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
01.05.25 - PR Newswire
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" PR Newswire
01.05.25 - PR Newswire
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV PR Newswire
29.04.25 - PR Newswire
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA) PR Newswire
29.04.25 - PR Newswire
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV PR Newswire
28.04.25 - PR Newswire
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire
25.04.25 wallstreetONLINE Redaktion
Geschäftszahlen: AbbVie überrascht mit Quartals­zahlen: So viel Gewinn hat niemand erwartet!
AbbVie hat am Freitag seine Ergebnisse für das erste Quartal veröffentlicht. Das Biopharma-​Unternehmen liefert knackige Zahlen. Das freut die Anleger!Das Unternehmen meldet ...
25.04.25 - PR Newswire
AbbVie Reports First-Quarter 2025 Financial Results
AbbVie Reports First-​Quarter 2025 Financial Results PR Newswire
25.04.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV PR Newswire

Newssuche

Videos

newspaper
19.03.26
COUNTER HUNTER Strategie Einführung
Live-​Seminar am 29.3. ab 14 Uhr! Wie immer wird die Schulung auch aufgezeichnet und allen ... Mehr »